In addition, the mutation of tumor protein p53 (TP53) and tumor proportion score (TPS) of programmed death ligand-1 (PD-L1) are also closely related to lung cancer treatment decisions [6,7,8,9]. This evidence concerns the gene TP53 and neoplasm.